diflunisal has been researched along with flufenamic acid in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 10 (55.56) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Buttar, D; Colclough, N; Gerhardt, S; MacFaul, PA; Maskos, K; Phillips, SD; Plowright, A; Steinbacher, S; Steuber, H; Tam, K; Whittamore, P | 1 |
| Choi, S; Kelly, JW | 1 |
| Arsequell, G; Blasi, D; Bosch, L; Centeno, NB; Cotrina, EY; Pinto, M; Planas, A; Quintana, J; Valencia, G; Vilà, M | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Choi, S; Connelly, S; Johnson, SM; Kelly, JW; Mortenson, DE; Powers, ET; Wilson, IA | 1 |
| Mizuguchi, M; Yokoyama, T | 1 |
| Brustenga, C; Frédérick, R; Liberelle, M; Savoyen, P; Sonveaux, P; Thabault, L; Van Gysel, M; Wouters, J | 1 |
| Barlow, JW; Craik, DJ; Hall, JG; Lim, CF; Munro, SL; Stockigt, JR; Topliss, DJ | 1 |
| Baures, PW; Kelly, JW; Oza, VB; Peterson, SA | 1 |
| Almeida, MR; Alves, I; Arsequell, G; Cardoso, I; Macedo, B; Planas, A; Saraiva, MJ; Valencia, G | 1 |
| Ikeda, S; Kelly, JW; Sekijima, Y; Tojo, K | 1 |
| Chiang, J; Farha, OK; Hawthorne, MF; Julius, RL; Perry, LJ | 1 |
| Hatzidimitriou, AG; Kefala, LA; Kessissoglou, DP; Papadopoulos, AN; Perdih, F; Psomas, G; Tsiliou, S; Turel, I | 1 |
2 review(s) available for diflunisal and flufenamic acid
| Article | Year |
|---|---|
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
Transthyretin Amyloidogenesis Inhibitors: From Discovery to Current Developments.
Topics: Amyloid; Crystallography, X-Ray; Drug Discovery; Humans; Molecular Structure; Prealbumin | 2020 |
16 other study(ies) available for diflunisal and flufenamic acid
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
Topics: Binding Sites; Crystallography, X-Ray; Drug Interactions; Humans; Pharmaceutical Preparations; Protein Binding; Protein Structure, Tertiary; Serum Albumin; Spectrometry, Fluorescence | 2010 |
A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.
Topics: Amyloid; Humans; Kinetics; Models, Molecular; Prealbumin; Protein Interaction Domains and Motifs; Protein Structure, Quaternary; Spectrometry, Fluorescence; Stilbenes | 2011 |
Modulation of the fibrillogenesis inhibition properties of two transthyretin ligands by halogenation.
Topics: Diflunisal; Flufenamic Acid; Halogenation; Humans; Kinetics; Ligands; Models, Molecular; Prealbumin; Protein Multimerization; Protein Structure, Secondary; Structure-Activity Relationship | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
Topics: Amyloid Neuropathies, Familial; Computer Simulation; Drug Design; Humans; Molecular Docking Simulation; Prealbumin; Protein Multimerization; Protein Stability; Small Molecule Libraries | 2017 |
Discovery of small molecules interacting at lactate dehydrogenases tetrameric interface using a biophysical screening cascade.
Topics: Fluorometry; Lactate Dehydrogenases; Ligands; Magnetic Resonance Spectroscopy | 2022 |
Drug competition for thyroxine binding to transthyretin (prealbumin): comparison with effects on thyroxine-binding globulin.
Topics: Binding Sites; Binding, Competitive; Biological Transport; Diflunisal; Flufenamic Acid; Hydrogen-Ion Concentration; Mefenamic Acid; Prealbumin; Salicylates; Structure-Activity Relationship; Thyroxine; Thyroxine-Binding Proteins; Triiodothyronine | 1989 |
Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid.
Topics: Amyloid; Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Diflunisal; Drug Design; Drug Evaluation, Preclinical; Flufenamic Acid; Humans; Light; Niflumic Acid; Prealbumin; Scattering, Radiation; Structure-Activity Relationship; Sulindac; Tolmetin | 1999 |
Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative.
Topics: Amyloid Neuropathies; Diclofenac; Diflunisal; Flufenamic Acid; Humans; Iodine; Iodobenzoates; Molecular Structure; Prealbumin; Protein Binding; Thyroxine | 2004 |
Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis.
Topics: Adult; Aged; Amyloid beta-Peptides; Amyloid Neuropathies, Familial; Anti-Inflammatory Agents, Non-Steroidal; Chromium; Diflunisal; Female; Flufenamic Acid; Humans; Hydrogen-Ion Concentration; Iron; Male; Middle Aged; Mutation; Prealbumin; Protein Denaturation | 2006 |
Synthesis and evaluation of transthyretin amyloidosis inhibitors containing carborane pharmacophores.
Topics: Amyloid; Anti-Inflammatory Agents, Non-Steroidal; Boranes; Cyclooxygenase 1; Cyclooxygenase 2; Diflunisal; Flufenamic Acid; Humans; Hydrogen-Ion Concentration; Prealbumin | 2007 |
Cobalt(II) complexes with non-steroidal anti-inflammatory drugs and α-diimines.
Topics: 2,2'-Dipyridyl; Aminopyridines; Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Biphenyl Compounds; Cations, Divalent; Cobalt; Coordination Complexes; Crystallography, X-Ray; Diflunisal; DNA; Flufenamic Acid; Free Radical Scavengers; Intercalating Agents; Kinetics; Mefenamic Acid; Methanol; Models, Molecular; Niflumic Acid; Phenanthrolines; Picrates; Serum Albumin | 2016 |